Sareum today announced the successful dosing of the first subjects in the multiple ascending dose part of its Phase 1a clinical trial for its lead programme SDC-1801. Dosing has started at a specialist clinical unit in Melbourne, Australia, and subjects will receive SDC-1801 orally once daily for 10 days. This follows approval by the safety review committee granted upon review of preliminary data generated from the three initial cohorts in the single ascending dose part of the study. The commit ....